Immunohistochemical Detection of HER1/HER2 Can Be Considered a Predictive Marker of Gefitinib Activity in Non-Small-Cell Lung Cancer?
- 1 February 2005
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (4) , 921-922
- https://doi.org/10.1200/jco.2005.05.700
Abstract
No abstract availableThis publication has 2 references indexed in Scilit:
- Gefitinib in Recurrent Non–Small-Cell Lung Cancer: An IDEAL Trial?Journal of Clinical Oncology, 2003
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003